JACC. Case reports · 2025
Stanford Type A Aortic Dissection During Adjuvant Capecitabine Chemotherapy for Colorectal Cancer.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kawaguchi Yasuhiko, Fukumoto Yuichiro, Aichi Chiaki, Konakano Kazuya, Tamaki Mototsugu, Kitamura Hideki, Okawa Yasuhide
Аннотация
BACKGROUND: Capecitabine, an oral prodrug of 5-fluorouracil, is widely used for gastrointestinal malignancies. While its coronary toxicity is well documented, large-vessel complications such as aortic dissection are rarely reported.
CASE SUMMARY: We present a 65-year-old man with colorectal cancer who developed Stanford type A aortic dissection 3 days after initiating adjuvant capecitabine therapy. Imaging revealed extensive dissection from the ascending to the abdominal aorta. Emergency hemiarch replacement was successfully performed.
DISCUSSION: The absence of prior cardiovascular disease, close temporal relationship, and known vasotoxicity of fluoropyrimidines suggest a likely association. Fluoropyrimidines may induce endothelial injury, vasospasm, and hypertension. A history of smoking in our patient may have contributed to vascular susceptibility.
TAKE-HOME MESSAGES: Capecitabine, though well tolerated, may rarely cause life-threatening vascular complications such as aortic dissection. Clinicians should maintain a high index of suspicion for atypical vascular symptoms during therapy.
CASE SUMMARY: We present a 65-year-old man with colorectal cancer who developed Stanford type A aortic dissection 3 days after initiating adjuvant capecitabine therapy. Imaging revealed extensive dissection from the ascending to the abdominal aorta. Emergency hemiarch replacement was successfully performed.
DISCUSSION: The absence of prior cardiovascular disease, close temporal relationship, and known vasotoxicity of fluoropyrimidines suggest a likely association. Fluoropyrimidines may induce endothelial injury, vasospasm, and hypertension. A history of smoking in our patient may have contributed to vascular susceptibility.
TAKE-HOME MESSAGES: Capecitabine, though well tolerated, may rarely cause life-threatening vascular complications such as aortic dissection. Clinicians should maintain a high index of suspicion for atypical vascular symptoms during therapy.